UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.00001 par value per share CTMX Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE S ...

Conditionally Activated Therapeutics for the treatment of cancer 1 © 2020 CytomX Therapeutics, Inc. Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, preclinical and clinical pipeline and milestones, regulatory obj ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2021 Earnings Conference Call August 5, 2021 5:00 PM ET Company Participants Chau Cheng - Vice President Investor Relations & Corporate Communications Sean McCarthy - President, Chief Executive Officer & Chairman Amy Peterson - Chief Development Officer Carlos Campoy - Chief Financial Officer Conference Call Participants Anupam Rama - JP Morgan Roger Song - Jefferies Joe Catanzaro - Piper Sandler Cynthia Chen - Cowen Paul Jeng - Guggenheim Peter Lawson - Barclays ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 27-3521219 (State or other jurisdiction of incorporation or organiz ...

Financial Performance - Revenues for the three months ended March 31, 2021, were $15,971 thousand, a decrease of 67.8% compared to $49,593 thousand for the same period in 2020 [22]. - Total operating expenses decreased to $31,598 thousand for the three months ended March 31, 2021, down 39.7% from $52,386 thousand in the same period in 2020 [22]. - The net loss for the three months ended March 31, 2021, was $15,554 thousand, compared to a net income of $12,205 thousand for the same period in 2020 [22]. - The company reported a comprehensive loss of $15,550 thousand for the three months ended March 31, 2021, compared to a comprehensive income of $12,484 thousand for the same period in 2020 [22]. - Total revenue from collaboration partners for the three months ended March 31, 2021, was $15.971 million, a decrease of 67.8% compared to $49.593 million for the same period in 2020 [68]. - The Company recognized revenue of $1.2 million related to the AbbVie Agreements for the three months ended March 31, 2021, compared to $30.1 million for the same period in 2020 [76]. - The Company recognized revenue of $4.8 million for the three months ended March 31, 2021, compared to $0.4 million for the same period in 2020 [89]. - The Company recognized revenue of $7.4 million for the three months ended March 31, 2021, compared to $17.4 million for the same period in 2020 [100]. - Revenue from AbbVie decreased by $28.868 million primarily due to a $40 million milestone payment recognized in Q1 2020 [163]. - Revenue from Astellas increased by $4.369 million due to the recognition of an $80 million upfront payment over a five-year estimated research service period [163]. - Revenue from Bristol Myers Squibb decreased by $10 million primarily due to the full recognition of a $10 million milestone payment in February 2020 [163]. Assets and Equity - Total current assets increased to $400,008 thousand as of March 31, 2021, from $324,013 thousand as of December 31, 2020, representing a 23.5% increase [19]. - Cash and cash equivalents increased to $329,666 thousand as of March 31, 2021, from $191,859 thousand as of December 31, 2020, marking a 71.8% increase [19]. - Total stockholders' equity increased to $146,022 thousand as of March 31, 2021, from $49,803 thousand as of December 31, 2020, reflecting a significant increase of 193.5% [19]. - The total fair value of the Company's short-term investments as of March 31, 2021, was $346.248 million, an increase from $256.298 million as of December 31, 2020 [66]. - As of March 31, 2021, the company had cash, cash equivalents, and short-term investments totaling $393.8 million, an increase from $316.1 million as of December 31, 2020 [176]. Cash Flow - The company’s cash flows from operating activities resulted in a net cash used of $29,940 thousand for the three months ended March 31, 2021, compared to $49,737 thousand for the same period in 2020 [28]. - Cash used in operating activities was $29.9 million for the three months ended March 31, 2021, a decrease from $49.7 million in the same period of 2020 [180]. - Cash provided by investing activities was $59.0 million for the three months ended March 31, 2021, compared to $2.4 million in the same period of 2020 [184]. - Cash provided by financing activities amounted to $108.7 million during the three months ended March 31, 2021, primarily from a follow-on public offering [187]. Research and Development - Research and development expenses for the three months ended March 31, 2021, were $22.371 million, down $20.443 million from $42.814 million in the same period of 2020 [164]. - The decrease in research and development expenses was mainly due to a $11.2 million reduction in licensing expenses and an $8.5 million decrease in laboratory contracts and services [164]. - The company expects research and development expenses to increase substantially in the future as product candidates advance through clinical trials [151]. - The company has not experienced any material differences between accrued costs and actual costs incurred in research and development activities [53]. - Research and development expenses include costs directly attributable to R&D programs, with all costs expensed as incurred [54]. Clinical Trials and Product Development - The lead product candidates, praluzatamab ravtansine and CX-2029, are currently in Phase 2 clinical studies [132]. - The company is currently enrolling patients in a three-arm study for praluzatamab ravtansine, targeting approximately 40 evaluable patients per arm [133]. - CX-2043, a preclinical agent, has shown potent anti-tumor activity but will not have an IND submission in 2021 due to manufacturing delays [135]. - The company has paused new patient enrollment in its Phase 2 clinical trial of praluzatamab ravtansine due to COVID-19, which has caused delays in patient recruitment and clinical site initiations [208]. - The company relies on third parties for conducting clinical trials and preclinical studies, and any failure by these parties could materially affect its development programs [203]. - The company has not yet demonstrated the ability to successfully complete clinical trials or obtain regulatory approvals for its product candidates [215]. - The company’s approach to therapeutic treatment development is based on unproven novel technologies, which may not result in marketable products [203]. Market and Competition - The company faces competition from other entities developing cancer treatments, which could adversely affect its ability to commercialize its product candidates [203]. - The actual probability of success for product candidates may be affected by various factors, including safety, efficacy, and competition [151]. - The COVID-19 pandemic may continue to disrupt the company’s research and clinical trials, impacting its financial condition and operational capabilities [212]. - The company’s stock price may be volatile, potentially leading to substantial losses for purchasers of its common stock [203]. Financial Obligations and Future Outlook - The company has an accumulated deficit of $465.7 million as of March 31, 2021, up from $450.1 million at the end of 2020, indicating ongoing significant operating losses [213]. - The company does not expect to generate revenue from product sales until product candidates have advanced through clinical development and obtained regulatory approval [148]. - The company expects to need to raise substantial additional funds to advance the development of its product candidates, with no guarantee that this funding will be available on acceptable terms [217]. - The company has not entered into any off-balance sheet arrangements and does not have holdings in variable interest entities [190]. - There were no material changes in contractual obligations during the three months ended March 31, 2021, compared to the previous year [188].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |-----------------------------------------------------------------------|----------------------------------------------------------------------------------|------------------ ...

39th Annual J.P. Morgan Healthcare Conference Sean McCarthy, D.Phil. President, Chief Executive Officer, and Chairman JANUARY 14, 2021 © 2021 CytomX Therapeutics, Inc. Conditionally-Active Antibody Therapeutics for the treatment of cancer © 2020 CytomX Therapeutics, Inc. Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Stephanie Ascher - Investor Relations Sean McCarthy - President & Chief Executive Officer Amy Peterson - Chief Financial Officer Carlos Campoy - Senior Vice President & Chief Financial Officer Conference Call Participants Terence Flynn - Goldman Sachs Mara Goldstein - Mizuho Etzer Darout - Guggenheim Securities Operator Ladies and gentlemen, thank you for standing by, and welcome to the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | --- | |--------------------------------------------------------------------------------------------------------------|----------------------------------------- ...

REIMAGINING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER Wedbush PacGrow Healthcare Conference AUGUST 12, 2020 © 2020 CytomX Therapeutics, Inc. 1 Forward Looking Statement This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, preclinical a ...